Close Menu

IPO

The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.

The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.

The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.

The expected gross proceeds are more than double what the firm proposed as its original goal for the offering when it filed plans to list its shares in September.

The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.

The company said it plans to list its stock on the Nasdaq under the ticker symbol GH.

The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.

The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.

The center is an international joint venture established in 2013 between South Korean clinical lab Eone Life Science and California-based Diagnomics.

In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.